Clinical Trial

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Study acronym: TRIUMPH-8
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-18
Trial Details
NCT Number NCT07232719
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight
Enrollment 250 participants
Start Date 2025-11-17
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-17